

=> b reg
FILE 'REGISTRY' ENTERED AT 17:02:31 ON 22 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JAN 2008 HIGHEST RN 1000370-19-3
DICTIONARY FILE UPDATES: 21 JAN 2008 HIGHEST RN 1000370-19-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>


=> d que sta 18
L1 STR



VAR G1=0/S
REP G2=(1-2) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L3 2510 SEA FILE=REGISTRY SSS FUL L1
L4 STR



VAR G1=0/S
REP G2=(1-2) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E4 C E2 N AT 16

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L6 161 SEA FILE=REGISTRY SUB=L3 SSS FUL L4
L7 143 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND 46.150.18/RID
L8 140 SEA FILE=REGISTRY ABB=ON PLU=ON L7 AND NC2NC2/ES

=> b hcap
FILE 'HCAPLUS' ENTERED AT 17:02:42 ON 22 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jan 2008 VOL 148 ISS 4
FILE LAST UPDATED: 21 Jan 2008 (20080121/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs fhitstr hitrn 119 tot

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2006:1354308 HCAPLUS
 DN 146:100725
 TI Preparation of anilino pyrimidine derivatives for treatment of Hepatitis C virus
 IN Kim, Jong Woo; Lee, Sang Wook; Lee, Geun Hyung; Han, Jae Jin; Park, Sang Jin; Park, Eui Yong; Shin, Joong Chul
 PA B & C Biopharm. Co., Ltd. S. Korea
 SO PCT Int. Appl. 49pp.
 COOPEN PIXXD2
 DT Patent
 LA English
 FAN,CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2006135706	A1	20061228	2006WO-FR02416	20060622
RW: AT, BE, BG, CH, CY, CR, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CY, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, GM, KE, LS, LU, MW, NA, SD, SL, SZ, TZ, US, ZM, ZW, AM, AZ, BY, RG, KZ, MD, RU, TJ, TM	B1	20070328	2005KR-0054885	20050624
PRAI 2005KR-0054885	A			
OS MARPAT 146:100725				
GI				





AB Title compds. represented by the formula I [wherein R1 = -(NR2)-CH2-n-R3, R = H, -R4-Het-1-yl or (un)substituted heteraryl; R2 = H, benzyl or alkyl; R3 = H, halogen, OH, etc.; R4 = H, carbamoyl, alkyl, etc.; n = 0-4; Het = piperazine, morpholine, pyrazine, pyrazolin, etc.; (un)substituted hetero] were prepared. For example, I (R1 = MeNH) was provided in a multi-step synthesis starting from the reaction of 4,6-dichloro-2-(methylsulfonyl)pyrimidine with 4-(morpholinol)aniline. The prepared title compds. showed inhibitory effect on activity of HCV RNA polymerase in vitro and low toxicity. The can be advantageously used as a therapeutic or prophylactic agent of hepatitis C virus.

IT 917594-57-1P, 2-Methylthio-6-[4-(morpholinol)anilino]-4-[4-((1-piperazinyl)carbonyl)methyl]piperazin-1-ylpyrimidine
 917594-58-2P, 2-Methylthio-6-[4-(morpholinol)anilino]-4-[4-((1-methylpiperidino)carbonyl)methyl]piperazin-1-ylpyrimidine
 917594-59-3P, 2-Methylthio-6-[4-(morpholinol)anilino]-4-[4-((4-hydrazinylmethyl)pyrazidin-1-yl)carbonyl]piperazin-1-ylpyrimidine
 917594-60-4P, 2-Methylthio-6-[4-(morpholinol)anilino]-4-[4-((4-carbamoylmethyl)pyrazidin-1-yl)carbonyl]piperazin-1-ylpyrimidine
 917594-61-7P, 2-Methylthio-6-[4-(morpholinol)anilino]-4-[4-((1-pyrrololidinyl)pyridin-1-yl)carbonyl]piperazin-1-ylpyrimidine
 917594-62-8P, 2-Methylthio-6-[4-(morpholinol)anilino]-4-[4-((4-oxazolyl)pyridin-1-yl)carbonyl]piperazin-1-ylpyrimidine
 917594-63-9P, 2-Methylthio-6-[4-(morpholinol)anilino]-4-[4-((morpholinopiperidino)carbonyl)methyl]piperazin-1-ylpyrimidine
 PL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of anilino pyrimidine derivs. for treatment of Hepatitis C virus)

RN 917594-57-1 HCAPLUS

L19 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS ON STN
 AN 2005:4703969 HCAPLUS
 DN 143:26636
 TI Preparation of 4-((Arylethyl)aminomethyl)piperidines as inhibitors of NGF binding (neurotrophin receptor) to p75NTR (p75 neurotrophic) receptor for treating p75NTR related diseases
 IN Bosch, Michael; Waggon, Jean
 PA Sanofi-Synthelabo, Fr.
 SO Fr. Demande, 31 pp.
 COOPEN: FRXXBL
 DT Patent
 LA French
 FAN,CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR---2829268	A1	20050603	2003FR-0014172	20031201
FR---2829268	B3	20060804		
PI WO2005054229	A1	20050616	2004WO-FR03066	20041130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MM, MX, ME, NA, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TE, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, ZR, ZT, ZU, ZW, ZY	EE, ES, FI, FR, GR, IT, LU, NL, SE, MC, PI, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, SN, QD, GW, ML, MR, NE, SN, TD, TG	IT 852936-29-9, [(1-Methyl-1H-pyrrol-2-yl)methyl][(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine PL: PAC (Pharmacological activity); SPPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of 4-((arylethyl)aminomethyl)piperidines as binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)	
PRAI 2005054229	A	20031201	2006US-0420505	20060526
OS MARPAT 143:26636	W	20041130		
GI				



AB Title compds. I (wherein X = (CH2)n; n = 1-2; R1 = CF3; R2 = H, alkyl; R3 = (un)substituted pyrrolyl, 1,2,3-thiadiazolyl, pyrazinyl, etc.; and their

L19 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 CN 852936-29-9P, 1-(1-Methyl-1H-pyrrol-2-yl)methyl][(1-[(4-(pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine
 852936-30-0P, [(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine
 852936-31-1P, [(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine
 852936-32-2P, [(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine
 852936-33-3P, [(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine
 852936-34-4P, [(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine
 852936-35-5P, [(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]amine
 852936-36-6P, [(4-Dimethyl-2-furyl)methyl]methanimine
 852936-37-7P, [(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]methanimine
 852936-38-8P, [(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]methanimine
 852936-39-9P, [(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]methanimine
 852936-40-4B, 1-Phenyl-1-[(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]methanimine
 852936-41-5B, 1-[(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]methanimine
 852936-42-6B, N-Methyl-1-[(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]methanimine
 852936-43-7B, N-Methyl-1-[(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]methanimine
 852936-44-8B, N-Methyl-1-[(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)-N-(pyridin-4-yl)methyl]methanimine
 852936-45-9B, N-Methyl-1-(pyrazin-2-yl)-N-[(1-[(4-(Pyrazin-2-yl)piperazin-1-yl)acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl)methyl]methanimine
 852936-46-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-47-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-48-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-49-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-50-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-51-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-52-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-53-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-54-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-55-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-56-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-57-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-58-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-59-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-60-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-61-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-62-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-63-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-64-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-65-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-66-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-67-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-68-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-69-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-70-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-71-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-72-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-73-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-74-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-75-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-76-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-77-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-78-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-79-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-80-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-81-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-82-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-83-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-84-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-85-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-86-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-87-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-88-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-89-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-90-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-91-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-92-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-93-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-94-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-95-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-96-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-97-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-98-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-99-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-100-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-101-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-102-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-103-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-104-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-105-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-106-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-107-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-108-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-109-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-110-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-111-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-112-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-113-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-114-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-115-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-116-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-117-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-118-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-119-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-120-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-121-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-122-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-123-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-124-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-125-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-126-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-127-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-128-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-129-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-130-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-131-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-132-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-133-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-134-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-135-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-136-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-137-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-138-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-139-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-140-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-141-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-142-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-143-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-144-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-145-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-146-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-147-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-148-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-149-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-150-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-151-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-152-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-153-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-154-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-155-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-156-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-157-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-158-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-159-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-160-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-161-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-162-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-163-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-164-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-165-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-166-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-167-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-168-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-169-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-170-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-171-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-172-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-173-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-174-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-175-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-176-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-177-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-178-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-179-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-180-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-181-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-182-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-183-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-184-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-185-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-186-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-187-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-188-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-189-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-190-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-191-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-192-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-193-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-194-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-195-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-196-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-197-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-198-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-199-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-200-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-201-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-202-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-203-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-204-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-205-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-206-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-207-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-208-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-209-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-210-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-211-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-212-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-213-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-214-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-215-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-216-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-217-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-218-2B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-219-3B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-220-4B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-221-5B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-222-6B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-223-7B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-224-8B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-225-9B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-226-0B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-227-1B, (4-Methylpyridin-2-yl)methanimine tetrahydrochloride
 852936-228-2B, (4-M

L19 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 634469-80-0P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
RL: S60 (Synthetic preparation); P60 (Preparation)
(Intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
IT 634469-81-1P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone Trihydrate
RL: S60 (Synthetic preparation); P60 (Preparation)
(Preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10 / 516704


=> d bib abs hitstr l17 tot

L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STIN

AN 2002:723424 HCAPLUS

DN 138:137143

TI Synthesis of N-substituted piperazinyl carbamoyl and acetyl derivatives of tetrahydropapaverine as potent antispasmodic agents
AU Kaur, Jasbir; Ghosh, Narendra Nath; Talwar, Anita; Chandra, Ramesh
CS Dr. B. R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, 110007, India
SO Chemical & Pharmaceutical Bulletin (2002), 50(9), 1223-1228
CODEN: CPTAL; ISSN: 0009-2363
PB Pharmaceutical Society of Japan
DT Journal
LA English
OS CASREACT 138:137143
GI



I

AB The synthesis and structure-activity-relationship (SAR) for a series of N-substituted piperazinyl carbamoyl and piperazinyl acetyl derivs. of tetrahydropapaverine was carried out. Several synthetic methods of carbamoyl tetrahydropapaverine analogs involve N-substituted piperazines and carbamoyl imidazole tetrahydropapaverine as starting materials. Another route for synthesizing these compds., involving the formation of carbamoyl imidazole piperazine has also been explored. Acetyl tetrahydropapaverine was also synthesized by reaction with various piperazinyl moieties afforded the acetyl tetrahydropapaverine derivs. Variously substituted piperazines have been used to monitor the effect of electron releasing and electron withdrawing substituents upon the antispasmodic activity of the mols.. Effect of varying electron densities on the heterocyclic ring, allowing substitution of the ring groups on the benzene ring has also been monitored. Pharmacological methods involve the in vitro antispasmodic activity studies on a freshly removed guinea pig ileum using a force displacement transducer amplifier connected to a physiograph. Among the analogs synthesized in the present study, a promising compound I, a potent muscle relaxant as compared to papaverine, has been obtained.


IT 492464-25-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(Preparation of N-substituted piperazinyl carbamoyl and acetyl derivs. of tetrahydropapaverine as antispasmodic agents)

RN 492464-25-2 HCAPLUS

CN Isoquinoline, 1-[3-(4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-[(4-(2-pyrimidinyl)-1-piperazinyl)acetyl]- (9CI) (CA INDEX NAME)

L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STIN (Continued)

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STIN

AN 1989:594790 HCAPLUS

DN 111:194790

TI Preparation of N-[3-(heterocyclylcarbonyl- and -sulfonyl)propyl]-N'-2-pyrimidinylpiperazines as antianxiety agents

IN M. S. Khan, L. M. Mekwan

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 26 pp.

CODEN: EPXXW

DT Patent

LA English

CN 111:194790

PATENT NO. KIND DATE APPLICATION NO. DATE

PI EP-----334565 P2 19890503 1988EP-0309725 19881017

EP-----342623 A3 19900711 1988EP-0309725 19881017

EP-----34263 B3 19930407 1988EP-0309725 19881017

R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE

WO---8903831 A1 19890505 1987WO-US02855 19871026

W: PT, HU, NO, SU, US

HU-----50124 A2 19920330 1987HU-0006036 19871026

HU-----506109 B 19920282 1987HU-0006036 19871026

AT-----87919 T 19930415 1988AT-0309725 19881017

ES---2094823 T3 19940818 1988ES-0309725 19881017

IL---88085 A 19930222 1988IL-0088085 19881019

JP---901179 A 19900111 1988JP-0268008 19881024

JP---9013406 B 19940608 1988JP-0268008 19881024

CN---1062248 A 19900515 1988CN-0107386 19881024

CN---1062248 B 19930929 1988CN-0107386 19881024

ZA---8807925 A 19900627 1988ZA-0007925 19881024

DD---26398 A5 19900101 1988DD-0251025 19881024

DD---26397 A5 19900220 1988DD-0337989 19881024

CA---1314881 C 19930323 1988CA-0581091 19881024

AU---8824327 A 19890427 1988AU-0024327 19881025

AU---598161 B2 19900614 1988AU-0024327 19881025

DK---8805914 A 19890427 1988DK-0005914 19881025

DK---8805914 B1 19900106 1988DK-0005914 19881025

PL---152117 B1 199001130 1988PL-0275476 19881025

PL---153184 B1 19910329 1988PL-0279536 19881025

CS---271441 B2 19910411 1988CS-0007080 19881026

CS---274446 B2 19910413 1988CS-0007151 19881026

NO---285552 A 19910413 1990NO-0002562 19900421

US---4994455 A 19910219 1990US-0472835 19900421

RU---2039768 C1 19950227 1990RU-4743942 19900425

FI---94638 B 19950630 1990FI-0002070 19900425

FI---94638 C 1995110 1990FI-0002070 19900425


PRAI 198700-0309725 A 19880106 1988PR-0309725 19881024

1988ED-0309725 A 19882017 1988ED-0309725 19881024

1988CS-0007080 A3 19881026 1988CS-0007080 19881024

OS CASREACT 111:194790; MARPAT 111:194790

GI



AB The title compds. (I; R2 = RCO, R1602; R = 14 specific N-attached heterocyclics, e.g., pyrrolidino, piperidino, etc.) R1 = 7 specific N-alkyl or heteroalkyl, e.g., 4-(dimethylaminomethyl)piperazine, 4-(2-pyrimidinyl)piperazine, etc.) were prepared as antianxiety agents (no data). Br(CH2)3CO2Et was refluxed 4 h with H2O-separation with 1-(2-pyrimidinyl)piperazine in MeCOCH2CHMe2 containing Na2CO3 and KI to give 75% (R1 = Ph) of which was saponified and the product stirred 3 h at 0° and then coevaporated with 4,4-dimethylpiperidine in CH2Cl2 containing Et3N, 1-hydroxybenzotriazole, and DCC to give 4% I (R2 = 4,4-dimethylpiperidinocarboxyl).

IT 123319-56-2P

RL: SPN (Synthetic preparation); PREP (Preparation)


(Preparation of N-alkyl or heteroalkyl antianxiety agent)

RN 123319-56-2 HCAPLUS

CN Piperazine, 4-acetyl-1-[1-oxo-4-[(2-pyrimidinyl)-1-piperazinyl]butyl]-4-

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STIN (Continued)

phenyl- (9CI) (CA INDEX NAME)



=> b uspatall
FILE 'USPATFULL' ENTERED AT 17:03:13 ON 22 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:03:13 ON 22 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:03:13 ON 22 JAN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr 1-3 5 121

L21 ANSWER 2 OF 5 USPATIFULL on STN (Continued)

L21 ANSWER 3 OF 5 USPATFULL ON STN
AN 2005:203297 USPATFULL
TI Piperazineylacetylpiriperidine derivatives, their preparation and therapeutic use thereof
IN Bono, Françoise, Toulouse, FRANCE
Bosch, Michel, Marseille, FRANCE
Des Sauss, Virginie, Valerges, FRANCE
Herbert, Jean-Marc, Tournonfeuille, FRANCE
Nisato, Dino, Saint-Georges D'Orgues, FRANCE
Tonnerre, Bernard, Vailhaques, FRANCE
Wagnon, Jean, Montpellier, FRANCE
SAINT-JEAN, Yves, 75013 Paris, FRANCE (non-U.S. corporation)
P1 US-20050176292 A1 20050628 (10)
AI 2003US-00516704 A1 20030605 (10)
2003WO-FR00016705 20030605
PRAI 2002FR-000007001 20020607
DT Utility
FS APPLICATION
LNEP SAN JUAN, P.R., PATENT DEPARTMENT-MAIL CODE D-303A, ROUTE 202-206, P.O.
BOX 6800, BRIDGEPORT, NJ, 08807, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2901
CAS INVESTIGATION IS AVAILABLE FOR THIS PATENT.
AB The invention relates to substituted 1-piperazineylacetylpiriperidine derivatives of general formula (I) #STR1# in which: n is 1 or 2; p is 1 or 2;

R₈.sub.1 represents a halogen atom; a trifluoromethyl radical; a (C_{sub.1-2}C_{sub.4-8})alkyl; (C_{sub.1-2}C_{sub.4-8})alkoxy; a trifluoromethoxy radical;
 R₈.sub.2 represents a hydrogen atom or a halogen atom;
 R₈.sub.3 represents a hydrogen atom or a group —CH_{sub.2}R₈.sub.5; a group —NR₈.sub.2SR₈.sub.5; a group —NR₈.sub.2SR₈.sub.6R₈.sub.7; a group —NR₈.sub.2RCOR₈.sub.9; a group —NR₈.sub.2B(CNR₈.sub.10)R₈.sub.11; a group —CH_{sub.2}R₈.sub.2SR₈.sub.12; a group —CH_{sub.2}SR₈.sub.2B(CNR₈.sub.13)R₈.sub.14; a group —CH_{sub.2}SR₈.sub.2B(CNR₈.sub.13)R₈.sub.15; a (C_{sub.1-2}C_{sub.4-8})alkoxycarbonyl; a group —CONR₈.sub.2SR₈.sub.17; or else R₈.sub.3 constitutes a double bond between the carbon atom to which it is attached and the carbon atom to which the ring is attached;
 R₈.sub.4 represents an aromatic group selected from: **#ASTR#4**
 R₈.sub.5 the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C_{sub.1-2}C_{sub.4-8})alkyl; (C_{sub.1-2}C_{sub.4-8})alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 634461-23-7, 1-[4-(Aminomethyl)-4]-[3-(trifluoromethyl)phenyl]-1-piperidinyl-2-[4-(pyrazinyl)-1-piperazinyl]-1-ethanone
 634461-63-5 634461-69-1P 634462-72-9P
 634462-91-0 634462-92-1P 634463-19-7P
 634463-19-1P 634463-49-3P 634464-60-1P
 634464-66-2P 634525-03-4P
 (NGF binding inhibitor; preparation of piperazineylacetylpirpidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by NGF)

IT 634461-24-8, 1-[4-(Aminomethyl)-4]-[3-(trifluoromethyl)phenyl]-1-piperazinyl-1-[4-(3-(trifluoromethyl)phenyl)-1-piperidinyl]-1-ethanone monohydrochloride
 634461-18-0P, 1-[4-(Hydroxyacetyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl-3-[4-(2-(pyrazinyl)-1-piperazinyl)-1-propanone oxalate
 634461-29-2P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl-3-[4-(2-(pyrazinyl)-1-piperazinyl)-1-ethanone
 634461-30-3P, 1-[4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl-3-[4-(2-(pyrazinyl)-1-piperazinyl)-1-ethanone
 Trihydrochloride 634461-52-2P 634461-53-3P
 634461-73-7P 634461-76-0P 634461-81-7P
 634461-87-3P 634461-93-1P 634461-99-7
 634462-26-3P 634462-32-10P 634462-38-7P
 634462-49-2P, 2-[4-(2-(Pyridinyl)-1-piperazinyl)-1-[4-(3-(trifluoromethyl)phenyl)-1-piperidinyl]-1-ethanone monohydrochloride 634462-55-6P 634462-61-6P
 634462-68-3P 634462-79-6P, 1-[4-(Hydroxymethyl)-4-[3-

L23 ANSWER 3.5 USP/ATF on STN (Continued)
 (trifluoromethylphenyl)-1-piperidinyl-2-(4-(2-pyrazinyl)-1-piperazinyl)-1-ethanone 634462-83-2D 1-[4-((Dimethylamino)methyl)-4]-[3-(trifluoromethylphenyl)-1-piperidinyl-2-(4-(2-pyrazinyl)-1-piperazinyl)-1-ethanone] 634463-24-1 1-[4-(4-Chlorophenyl)-3-(6-dihydro-2H-pyridinyl)-2-(4-(2-pyrazinyl)-1-piperazinyl)-1-ethanone] 634463-09-3 1-(4-(Aminomethyl)-4-(4-chlorophenyl)-1-piperidinyl)-2-(4-(2-pyrazinyl)-1-piperazinyl)-1-ethanone
 Trifluoracetate 634463-13-1P 634463-23-3P
 634463-44-2P 634463-55-1P 634463-77-7P
 634464-08-2P 634464-29-3P 634464-33-4P
 634464-08-2D 1-[4-((Methylamino)methyl)-4]-[3-(trifluoromethylphenyl)-1-piperidinyl]-2-(4-(2-pyrazinyl)-1-piperazinyl)-1-ethanone 634464-35-6P 1-[4-((Isopropylamino)methyl)-4]-[3-(trifluoromethylphenyl)-1-piperidinyl]-2-(4-(2-pyrazinyl)-1-piperazinyl)-1-ethanone 634464-20-3P 1-[4-(N-Methylisopropylamino)methyl]-4-(trifluoromethylphenyl)-1-piperidinyl]-2-(4-(2-pyrazinyl)-1-piperazinyl)-1-ethanone 634464-24-7P
 634464-29-2P 634464-34-9P 634464-39-4P
 634464-44-1P 634464-48-5P 1-[4-(Aminomethyl)-4-(3-chlorophenyl)-1-piperidinyl]-2-(4-(2-pyrazinyl)-1-piperazinyl)-1-ethanone 634464-72-5P 1-[4-(Aminomethyl)-4-(3-methoxyphenyl)-1-piperidinyl]-2-(4-(2-pyrazinyl)-1-piperazinyl)-1-ethanone Dioxalate 634470-24-1P 634470-42-1P 634525-09-9P
 (NFG binding inhibitor; prepn. of piperazinylacypiperidines as inhibitors of the binding of NGF to p75^{NR} receptor and of the

IT 634462-48-9; 634463-71-0; 634465-50-49
 apoptosis induced by NGF)
 4-piperidinocarbonitrile 634469-57-1, *p*-tert-Butyl
 {[1-(2-[4-(2-pyrazinyl)-1-piperazinyl]-1-oxyethyl)-4-[3-(
 trifluoromethyl)phenyl]-4-piperidinyl]methyl}carbamate
 634469-58-2, 4-[3-(2-pyrazinyl)-1-piperazinyl]acetyl)-4-[3-(
 trifluoromethyl)phenyl]-4-piperidinylmethyl carbamate
 634469-60-4, 4-[3-(2-pyrazinyl)-1-piperazinyl]acetyl)-4-[3-(
 trifluoromethyl)phenyl]-4-(4-Chlorophenyl)-1-[2-[4-(
 2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinylmethyl carbamate
 634469-61-5, *p*-tert-Butyl {[1-(2-[4-(2-pyrazinyl)-1-
 piperazinyl]-1-oxyethyl)-4-[3-(trifluoromethyl)phenyl]-4-
 piperidinyl]methyl}carbamate 634469-70-2, 4-(3-Chlorophenyl)-1-[
 2-[4-(2-pyrazinyl)-1-piperazinyl]acetyl]-4-piperidinylcarbonitrile
 634469-91-1, 4-[3-(3-chlorophenyl)-1-piperazinyl]-1-
 piperidinylmethyl carbamate
 (intermediate; preparation of piperazinylacetyl piperidines as inhibitors of
 the binding of NGF to p75NTR receptor and the apoptosis induced by

IT 634469-80-0P, 1-[4-(Aminomethyl)-4-phenyl-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
(intermediate; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the apoptosis induced by

the binding of NGF to p75⁺NTR receptor and of the apoptosis induced by NGF.

IT 634461-23-7, 1-(4-(Aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-

II 0374-13-4); 1-[4-(aminohexyl)-4-(4-(2-piperidinyl)-1-piperazinyl)-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone
(NGF binding inhibitor; preparation of piperazinylacylpiperidines as inhibitors of the binding of NGF to p75NTR receptor and of the

RN 634461-23-7 USPATFULL
CN 4-Piperidinemethanamine, 1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-

(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)


Digitized by srujanika@gmail.com

The diagram shows a six-membered carbon ring with two double bonds, one between the top-left and top-right carbons, and another between the bottom-left and bottom-right carbons.

Figure 1. A schematic diagram of the experimental setup. The light source (laser) emits a beam of light that passes through a lens and a beam splitter. The beam splitter splits the light into two paths: one path goes through a polarizer and a lens, and the other path goes through a lens and a polarizer. The two paths converge at a point where they are imaged by a camera.

$$\text{O} \quad \text{CH}_2-\text{NH}_2$$


L21 ANSWER 3 OF 5 USPATFULL on STN (Continued)



10 / 516704

=> d bib abs hitstr 4 121

L21 ANSWER 4 OF 5 USPATFULL on SIN
 AN 91:15162 USPATFULL
 II Anti-anxiety agents
 IN Welch, John Ellard M., Mystic, CT, United States
 DO Diversified Inc., New York, NY, United States (U.S. corporation)
 PI US--4994455 19910219
 AI 1990US-000477835 19900421 (7)
 1987WO-US0002855 19871026
 19900421 PCT 371 date
 19900421 PCT 102(e) date
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Ford, John M.
 LREP Richardson, Peter C., Ginsburg, Paul H., De Benedictis, Karen
 CLM Number of Claims: 13
 ECL Exempted Claim: 1,6
 DRWY No Drawings
 LN.CNT 557
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 123319-56-2P
 (preparation of, as antianxiety agent)
 RN 123319-56-2 USPATFULL
 CN Piperidine, 4-acetyl-1-[1-oxo-4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4-phenyl- (9CI) (CA INDEX NAME)



=> d his

```
(FILE 'HOME' ENTERED AT 16:49:27 ON 22 JAN 2008)

FILE 'REGISTRY' ENTERED AT 16:49:33 ON 22 JAN 2008
L1      STR
L2      22 L1
L3      2510 L1 FULL
        SAV TEM J704C1/A L3
L4      STR L1
L5      10 L4 SAM SUB=L3
L6      161 L4 FULL SUB=L3
L7      143 L6 AND 46.150.18/RID
L8      140 L7 AND NC2NC2/ES

FILE 'HCAPLUS' ENTERED AT 16:56:19 ON 22 JAN 2008
L9      1 US20050176722 /PN

FILE 'REGISTRY' ENTERED AT 16:56:29 ON 22 JAN 2008

FILE 'HCAPLUS' ENTERED AT 16:56:29 ON 22 JAN 2008
L10     TRA L9 1- RN :    228 TERMS

FILE 'REGISTRY' ENTERED AT 16:56:29 ON 22 JAN 2008
L11     228 SEA L10
L12     69 L11 AND L8
L13     71 L8 NOT L12

FILE 'HCAPLUS' ENTERED AT 16:56:49 ON 22 JAN 2008
L14     2 L12
L15     4 L13
        SEL HIT RN 3-4

FILE 'REGISTRY' ENTERED AT 16:58:11 ON 22 JAN 2008
L16     2 E1-2

FILE 'HCAPLUS' ENTERED AT 16:59:23 ON 22 JAN 2008
        SEL AN 3-4 L15
L17     2 E3-6 AND L15
L18     2 L15 NOT L17
L19     3 L14,L18

FILE 'HCAOLD' ENTERED AT 17:00:37 ON 22 JAN 2008
L20     0 L8

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 17:00:45 ON 22 JAN 2008
L21     5 L8
```

=>